DD contractures treated with CCH injections.
Methods: A retrospective study was conducted of patients with DD contractures of the hand treated with CCH injections in a single institution since its FDA approval from February 2010 to April 2014. All patients received the recommended dose of 0.58mg of CCH reconstituted per manufacturer guidelines and returned one day after injection for joint manipulation under local nerve blocks. Data for follow up at 7 and 30 days post-op and up to 4 years for patients who return seeking further therapy for recurrent symptoms were reviewed. (Table 1) . Fifteen patients returned to the clinic seeking additional therapy for recurrent joint contracture symptoms for 17 joints (17/109, 15.6%; 5 MCP; 12 PIP) over a span of 2 months to 4 years. Eleven joint contractures (10%) recurred within one year, 2 joint contractures (1.8%) recurred in the second year, 1 joint contracture (0.9%) recurred in the third year, and 3 joint contractures (2.8%) recurred in the fourth year. Recurrence was defined as a return of >20 degrees contraction in the setting of a palpable cord after initial successful treatment.
Conclusions:
Our five-year experience of CCH injections for DD contractures of the hand revealed full correction in 75% and partial correction in 23% of treated joints. The recurrence rate of contracture was 15.6% which represented patients who returned to the clinic for evaluation of recurrent contractures after initial successful treatment. These results are comparable to current surgical treatment modalities as well as previously published multi- 
